Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2010 1
2011 1
2015 1
2016 1
2017 3
2018 5
2019 11
2020 7
2021 8
2022 11
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Méndez-Vidal MJ, Tjulandin S, Hoon Park S, Melichar B, Hutson T, Alemany C, McGregor B, Powles T, Grünwald V, Alekseev B, Rha SY, Kopyltsov E, Kapoor A, Alonso Gordoa T, Goh JC, Staehler M, Merchan JR, Xie R, Perini RF, Mody K, McKenzie J, Porta CG. Choueiri TK, et al. Among authors: basappa ns. Lancet Oncol. 2023 Mar;24(3):228-238. doi: 10.1016/S1470-2045(23)00049-9. Lancet Oncol. 2023. PMID: 36858721 Clinical Trial.
Setting Research Priorities for Kidney Cancer.
Jones JM, Bhatt J, Avery J, Laupacis A, Cowan K, Basappa NS, Basiuk J, Canil C, Al-Asaaed S, Heng DYC, Wood L, Stacey D, Kollmannsberger C, Jewett MAS. Jones JM, et al. Among authors: basappa ns. Eur Urol. 2017 Dec;72(6):861-864. doi: 10.1016/j.eururo.2017.04.011. Epub 2017 May 8. Eur Urol. 2017. PMID: 28495043
Management algorithms for metastatic prostate cancer.
Malone S, Shayegan B, Basappa NS, Chi K, Conter HJ, Hamilton RJ, Hotte SJ, Saad F, So AI, Park-Wyllie L, Hew H, McLeod D, Gotto G. Malone S, et al. Among authors: basappa ns. Can Urol Assoc J. 2020 Feb;14(2):50-60. doi: 10.5489/cuaj.5840. Can Urol Assoc J. 2020. PMID: 31039111 Free PMC article. Review.
Perioperative chemotherapy for muscle invasive bladder cancer.
Rudzinski JK, Basappa NS, North S. Rudzinski JK, et al. Among authors: basappa ns. Curr Opin Support Palliat Care. 2015 Sep;9(3):249-54. doi: 10.1097/SPC.0000000000000148. Curr Opin Support Palliat Care. 2015. PMID: 26125306 Review.
Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement.
Lalani AA, Kapoor A, Basappa NS, Bhindi B, Bjarnason GA, Bosse D, Breau RH, Canil CM, Cardenas LM, Castonguay V, Chavez-Munoz C, Chu W, Dudani S, Graham J, Heng DYC, Kollmannsberger C, Lattouf JB, Morgan S, Reaume MN, Richard PO, Swaminath A, Tanguay S, Wood LA, Lavallée LT. Lalani AA, et al. Among authors: basappa ns. Can Urol Assoc J. 2023 May;17(5):E154-E163. doi: 10.5489/cuaj.8381. Can Urol Assoc J. 2023. PMID: 37185210 Free PMC article.
2022 American Society of Clinical Oncology (ASCO): Meeting highlights.
Black PC, Fallah-Rad N, Loblaw A, Kassouf E, Keyes M, Basappa NS, Swaminath A. Black PC, et al. Among authors: basappa ns. Can Urol Assoc J. 2022 Sep;16(9):E499-E504. doi: 10.5489/cuaj.8097. Can Urol Assoc J. 2022. PMID: 36122414 Free PMC article. No abstract available.
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K, Ernst MS, Navani V, Wells JC, Bakouny Z, Donskov F, Basappa NS, Wood LA, Meza L, Pal SK, Szabados B, Powles T, Beuselinck B, McKay RR, Lee JL, Ernst DS, Kapoor A, Yuasa T, Choueiri TK, Heng DYC. Takemura K, et al. Among authors: basappa ns. Eur Urol Oncol. 2023 Oct 30:S2588-9311(23)00217-1. doi: 10.1016/j.euo.2023.10.002. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37914579
58 results